Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer treatment could get easier: shot may replace IV infusion

NCT ID NCT06698042

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether a shot (subcutaneous injection) of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer that has high PD-L1 levels. About 67 participants will receive either the shot or IV treatment, and researchers will measure drug levels in the blood and monitor side effects. The goal is to see if the shot can offer a more convenient option without compromising safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

67 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC). * Measurable disease as assessed by the local site investigator/radiology. Exclusion Criteria: * Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements. * Received prior systemic anticancer therapy for their metastatic NSCLC. * Known additional malignancy that is progressing or has required active treatment within the past 3 years. * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Active autoimmune disease that has required systemic treatment in the past 2 years. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * Active infection requiring systemic therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer Non-small cell lung cancer

Contacts and locations

Locations

  • Ankara Bilkent Sehir Hastanesi ( Site 2503)

    Ankara, 06800, Turkey (Türkiye)

  • Beijing Peking Union Medical College Hospital ( Site 5000)

    Beijing, Beijing Municipality, 100730, China

  • CELAN,S.A ( Site 1104)

    Guatemala City, 01010, Guatemala

  • Centro Medico Integral De Cancerología (CEMIC) ( Site 1103)

    Quetzaltenango, 09002, Guatemala

  • Chongqing University Three Gorges Hospital ( Site 5018)

    Chongqing, Chongqing Municipality, 404000, China

  • Chungnam National University Hospital ( Site 3003)

    Daejeon, Taejon-Kwangyokshi, 35015, South Korea

  • Clínica Internacional - Sede San Borja ( Site 1002)

    Lima, 15036, Peru

  • Clínica San Antonio ( Site 1006)

    Trujillo, La Libertad, 13008, Peru

  • Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2501)

    Bornova, İzmir, 35100, Turkey (Türkiye)

  • Ehime University Hospital ( Site 4007)

    Tōon, Ehime, 791-0295, Japan

  • Fujian Province Cancer Hospital ( Site 5007)

    Fuzhou, Fujian, 350014, China

  • Fujita Health University Hospital ( Site 4004)

    Toyoake, Aichi-ken, 470-1192, Japan

  • Fukushima Medical University Hospital ( Site 4011)

    Fukushima, 960-1295, Japan

  • Gazi University Health Research and Application Center Gazi Hospital-Oncology ( Site 2502)

    Ankara, 06560, Turkey (Türkiye)

  • Gulhane Egitim Arastirma Hastanesi ( Site 2504)

    Ankara, 06010, Turkey (Türkiye)

  • HELIOS Klinikum Erfurt ( Site 2005)

    Erfurt, Thuringia, 99089, Germany

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 2500)

    Ankara, 06230, Turkey (Türkiye)

  • Hospital General Universitari Vall d Hebron ( Site 2450)

    Barcelona, 08035, Spain

  • Hospital Universitario Juan Ramon Jimenez ( Site 2453)

    Huelva, 21005, Spain

  • Hospital Universitario Virgen Macarena ( Site 2455)

    Seville, 41009, Spain

  • Hospital of the University of Occupational and Environmental Health, Japan ( Site 4010)

    Kitakyushu, Fukuoka, 807-8556, Japan

  • Huizhou Central People's Hospital ( Site 5004)

    Huizhou, Guangdong, 516001, China

  • INSTITUTO CATALAN DE ONCOLOGIA- L´HOSPITALET DE LLOBREGAT ( Site 2451)

    Barcelona, 08908, Spain

  • IPOR Instituto Peruano de Oncología & Radioterapia ( Site 1004)

    Lima, 15036, Peru

  • Illinois Cancer Care ( Site 0101)

    Peoria, Illinois, 61615, United States

  • Institutul Oncologic ( Site 2202)

    Cluj-Napoca, 400015, Romania

  • Jiangmen Center Hospital ( Site 5001)

    Jiangmen, Guangdong, 529030, China

  • Jilin Province Tumor Hospital ( Site 5014)

    Changchun, Jilin, 130000, China

  • Jinan Central Hospital ( Site 5012)

    Jinan, Shandong, 250013, China

  • Juntendo University Hospital ( Site 4003)

    Bunkyo, Tokyo, 113-8431, Japan

  • Kanagawa Cardiovascular and Respiratory Center ( Site 4002)

    Yokohama, Kanagawa, 236-0051, Japan

  • Kochi Medical School Hospital ( Site 4012)

    Nankoku, Kochi, 783-8505, Japan

  • Korea University Guro Hospital ( Site 3001)

    Seoul, 08308, South Korea

  • Liuzhou People's Hospital ( Site 5009)

    Liuzhou, Guangxi, 545006, China

  • MEDI-K ( Site 1101)

    Guatemala City, 01009, Guatemala

  • Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2305)

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • Miyagi Cancer Center ( Site 4000)

    Natori-shi, Miyagi, 981-1293, Japan

  • Montefiore Medical Center ( Site 0104)

    The Bronx, New York, 10461, United States

  • Narodowy Instytut Onkologii ( Site 2303)

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 4009)

    Sakai, Osaka, 591-8555, Japan

  • Oncosalud ( Site 1000)

    Lima, 15036, Peru

  • Onkologikoa - Instituto Oncologico de San Sebastian ( Site 2454)

    Donostia / San Sebastian, Gipuzkoa, 20014, Spain

  • Osaka International Cancer Institute ( Site 4005)

    Osaka, 541-8567, Japan

  • Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 1102)

    Guatemala City, 01010, Guatemala

  • Providence Medical Foundation ( Site 0117)

    Fullerton, California, 92835, United States

  • Pusan National University Hospital ( Site 3002)

    Pusan Kwangyokshi, Pusan-Kwangyokshi, 49241, South Korea

  • S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2201)

    Craiova, Dolj, 200746, Romania

  • SC Radiotherapy Center Cluj SRL ( Site 2203)

    Floreşti, Cluj, 407280, Romania

  • Saitama Prefectural Cancer Center ( Site 4001)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Shanghai Pulmonary Hospital ( Site 5010)

    Shanghai, Shanghai Municipality, 200433, China

  • Sichuan Cancer Hospital. ( Site 5006)

    Chengdu, Sichuan, 610213, China

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5021)

    Hangzhou, Zhejiang, 310016, China

  • Southern Medical University Nanfang Hospital ( Site 5003)

    Guangzhou, Guangdong, 510515, China

  • Spitalul Municipal Schuller Ploiești ( Site 2204)

    Ploieşti, Prahova, 100337, Romania

  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 2506)

    Istanbul, 34722, Turkey (Türkiye)

  • Taizhou Hospital of Zhejiang Province ( Site 5002)

    Linhai, Zhejiang, 317000, China

  • Takarazuka City Hospital ( Site 4006)

    Takarazuka, Hyōgo, 665-0827, Japan

  • The First Affiliated Hospital of Nanchang University ( Site 5019)

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated hospital of Xiamen University ( Site 5008)

    Xiamen, Fujian, 361003, China

  • The Royal Cornwall Hospital ( Site 2102)

    Truro, England, TR1 3LJ, United Kingdom

  • The first affiliated hospital, Sun Yat-Sen university ( Site 5011)

    Guangzhou, Guangdong, 510080, China

  • Tochigi Cancer Center ( Site 4008)

    Utsunomiya, Tochigi, 320-0834, Japan

  • Torbay Hospital ( Site 2100)

    Torquay, England, TQ2 7AA, United Kingdom

  • University of Cincinnati Medical Center ( Site 0112)

    Cincinnati, Ohio, 45219, United States

  • Universitätsklinikum Jena ( Site 2002)

    Jena, Thuringia, 07747, Germany

  • West China Hospital of Sichuan University ( Site 5016)

    Chengdu, Sichuan, 610041, China

  • Wuhan Union Hospital Cancer Center-Cancer Center ( Site 5015)

    Wuhan, Hubei, 430048, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.